[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416549":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Chrytèle RUBOD, MD,PhD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":16,"email":17},"CONTACT","0320445962","+33","chrystele.rubod@chru-lille.fr",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Hop Jeanne de Flandre Chu Lille","RECRUITING","Lisle-sur-Tarn","59037","France","FR",{"type":27,"coordinates":28},"Point",[29,30],1.80983,43.85347,{"lat":30,"lon":29},[33],{"name":7,"role":14,"phone":15,"phoneExt":7,"email":7},{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100416549","the-therapy-of-large-endometrioma-100416549",false,"NCT04704115","The Therapy of Large Endometrioma","Evaluate the Therapy of Large Ovarian Endometrioma","ENDOKYSTE","Inclusion Criteria:\n\n* Endometrioma size ≥ 6cm determined by MRI or ultrasonography\n* Women with isolated endometrioma or other extraovarian endometriosis: peritoneal, infiltrating endometriotic lesions and adenomyosis.\n* Cyst single or bilateral\n\nExclusion Criteria:\n\n* Cyst with radiographic or macroscopic in laparoscopy atypia\n* Pregnancy\n* Patient with contraindication to GnRH agonist (Enantone® 3,75 mg et Decapeptyl® 3 mg)\n* Patient with contraindication to laparoscopy\n* Patient with contraindication to general anesthesia\n* Subject refusing to participate in the study","FEMALE","18 Years","40 Years",{"count":48,"type":49},62,"ESTIMATED","OBSERVATIONAL","Endometrioma's prevalence is between 23 and 55%. It causes pelvic pain, decrease fertility and ovarian reserve.\n\nCurrently, there's no recommendation about large endometrioma's treatment and there's no information on the best treatment to limit recurrences, preserve fertility and ovarian reserve.\n\nIn Lille university hospital, simple laparoscopic drainage associated with hormonal therapy is practiced to reduce the risk of cystectomy.\n\nThis protocol will be evaluated with an observational and prospective study, including women of childbearing age having endometrioma measuring 6 cm or above.\n\nThe aim of this study is to assess if cyst drainage associated with GnRH agonist, could decrease endometrioma recurrences, deleterious effect on ovarian reserve and evaluate impact on anti-mullerian hormone",[53,54],"Endometrioma","Endometriosis Ovary",[56,57,58,59,60,61],"Endometriomas measuring 6 cm or more","Ovarian Endometrioma","laparoscopic drainage","recurrence","AMH","GnRH agonist therapy","2025-12-17",{"date":64,"type":65},"2025-12-23","ACTUAL",{"date":67,"type":65},"2021-01-21",{"date":69,"type":49},"2026-12",{"name":5,"class":6},1]